Study of Rina-S plus care for ovarian cancer maintenance
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer.
- Your cancer must have recurred more than 6 months after finishing first-line platinum therapy.
- If you have a BRCA mutation or HRD-positive cancer and achieved complete or partial response to first-line platinum, you must have already received PARP inhibitor maintenance therapy.
- You must have completed second-line platinum-based chemotherapy and be randomized within 8 weeks of the last dose.
- After second-line platinum therapy, you must have a complete response, partial response, or stable disease (stable disease only if you also received bevacizumab).
- You must not have had more than 2 prior lines of systemic therapy or progressed on your second-line regimen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
This trial compares a new drug called Rina-S with standard care to see if it helps keep ovarian cancer from coming back. It is for people who have finished their first round of platinum-based chemotherapy and are in remission or stable.
This trial tests a new experimental drug (JPI-547) combined with bevacizumab (a targeted therapy) as maintenance treatment for recurrent ovarian cancer after initial response to platinum-based chemo. The goal is to see if this combination can keep the cancer from growing longer than standard care.
This study tests whether adding a new pill (INCB123667) to the usual maintenance drug bevacizumab (Avastin) can keep ovarian cancer from coming back, compared to bevacizumab alone. It is for women who have finished their first chemo and are in remission or have stable disease.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.